This is the future of medicine. Novartis Pharmaceuticals company developed revolutionary new method- the first-ever treatment that genetically alters a patient’s own cells to fight cancer, transforming them into what scientists call “a living drug” that powerfully bolsters the immune system to shut down the disease.
Via IFLScience: “Through a range of different methods, the genes of the patient’s own cells are edited with breath-taking precision using synthetic viruses or CRISPR; these augmented cells are then reintroduced back into their bodies and their immune systems do the rest of the work.
Up until this point, gene therapy like this has remained experimental, meaning that it was only available to people taking part in a clinical trial. As reported by The New York Times, however, this is to no longer be the case: the Food and Drug Administration (FDA) is about to officially give the go-ahead for gene therapy to be put on the market for the very first time.
In this case, the therapy will be used to treat people suffering from an aggressive type of blood cancer named B-cell acute lymphoblastic leukemia. It will be made available to children and young adults aged between three and 25 who have been temporarily cured of the disease only to find that it has returned with a vengeance.
The treatment will be patient specific: Their own cells will be shipped off to be altered, frozen, then sent back to be reintroduced into the patient at a later date.”
This is something we’ve been waiting for. The potential of this new approach is that the patient’s cells are edited using synthetic viruses or CRISPR. This type of therapy is shown to cure children of seemingly incurable blood cancer.
It’s about time that the FDA approved it. Hopefully, when they do, this treatment will save thousands of children’s lives around the world.
This is why we need science! Real peer-reviewed science by dedicated, ethical researchers. Thank you.